# National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection

> **NCT02987530** · PHASE3 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 101 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Dolutegravir
- **DRUG:** Darunavir-cobicistat
- **DRUG:** Emtricitabine-Tenofovir

## Key facts

- **NCT ID:** NCT02987530
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-11
- **Primary completion:** 2019-07-30
- **Final completion:** 2020-01-31
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02987530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02987530, "National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02987530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*